GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? June 16, 2025 – February 20, 2026 What are the allegations? Robbins LLP is Investigating Allegations that Gossamer Bio, Inc. (GOSS) Misled Investors Regarding the Viability of its PROSERA Study According to the complaint, during the class period, defendants provided investors with material information concerning Gossamer’s Phase 3 PROSERA study evaluating seralutinib for the treatment
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Clinical Execution Failures: Levi & KorsinskyGlobeNewswire
- Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens BermanGlobeNewswire
- GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit — The Gross Law FirmGlobeNewswire
GOSS
Earnings
- 3/17/26 - Miss
GOSS
Sec Filings
- 4/9/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/24/26 - Form SCHEDULE
- GOSS's page on the SEC website